ライフサイエンスコーパス: control subject

1 ic studies (572 CHR patients and 480 healthy control subjects).

2 etry between 70 SZ and 46 MM/MS individuals (control subjects).

3 iers, and 82 demographically matched healthy control subjects.

4 V, and 6 patients with MPS VI) and 20 normal control subjects.

5 ifferences compared neutrophils from healthy control subjects.

6 rtical regions in CDSs compared with healthy control subjects.

7 Case-control study: 10 T2DM and 8 control subjects.

8 (n = 43) patients with AD versus age-matched control subjects.

9 xpression in patients with PAH compared with control subjects.

10 age 51 years and 90% women) and 342 matched control subjects.

11 pt of Parkinsonian signs compared to healthy control subjects.

12 in exertional increases in HR, in HFpEF and control subjects.

13 included 16,901 lung cancer cases and 20,965 control subjects.

14 nic erythromycin administration, and healthy control subjects.

15 iological changes, compared with age-matched control subjects.

16 nfected control subjects, and 14 noninfected control subjects.

17 ts with major depression relative to healthy control subjects.

18 tissue-factor positive MVs respectively than control subjects.

19 : Our study included 16,901 cases and 20,965 control subjects.

20 d lymphocytes in both patients with COPD and control subjects.

21 ients with sarcoidosis compared with matched control subjects.

22 sition in schizophrenia patients and healthy control subjects.

23 n and PCO were low and comparable to that in control subjects.

24 ients with IBD compared with that in healthy control subjects.

25 with MCI (B = -0.58; p = .002) compared with control subjects.

26 ellitus (DM) and DFU specimens compared with control subjects.

27 nes and/or chest-directed radiation) and 285 control subjects.

28 consisted of 125 Holocaust offspring and 31 control subjects.

29 ydrocortisone challenge (CORT) in 19 healthy control subjects.

30 A group of healthy subjects was used as control subjects.

31 smaller than those of MPS type IV and of the control subjects.

32 omeobox protein 1]: p < 0.001) compared with control subjects.

33 ompared with monocytes isolated from matched control subjects.

34 order who switched medication and 38 healthy control subjects.

35 s and girls relative to typically developing control subjects.

36 in the analysis with the appropriate matched control subjects.

37 ed using DTI in 39 DNFE schizophrenia and 31 control subjects.

38 FC) of 15 MDD and 15 matched non-psychiatric control subjects.

39 n patients with schizophrenia and in healthy control subjects.

40 t do not differ between patients and healthy control subjects.

41 ty-six patients with HL were matched to 7416 control subjects.

42 with first-episode psychosis and 20 healthy control subjects.

43 patients with PAH with GDF2 variants and in control subjects.

44 smaller than those of MPS type IV and of the control subjects.

45 from nine subjects with CF and five healthy control subjects.

46 ilitary veterans, relative to combat-exposed control subjects.

47 red between those with asthma or COPD versus control subjects.

48 arly or progressing Parkinson's disease, and control subjects.

49 on a different dataset of 612 HCM and 12,788 control subjects.

50 d subjects than responses seen in uninfected control subjects.

51 unmedicated; and 26 age, sex and IQ matched control subjects.

52 from 18 oral cancer patients and 15 healthy control subjects.

53 he severe and mild phenotypes, compared with control subjects.

54 had higher corrected IOP estimates than the control subjects.

55 ven Fabry disease and 19 age-matched healthy control subjects.

56 ) and MCI (B = 4.38; p < .001) compared with control subjects.

57 ubjects with type 2 diabetes mellitus and 20 control subjects.

58 a patients, 247 unaffected siblings, and 844 control subjects.

59 cations, having T2DM with complications, and control subjects.

60 thalassemia major patients compared with 29 control subjects.

61 unoglobulin (IVIG) treatment, and 23 matched control subjects.

62 igher negative valence compared with healthy control subjects.

63 opaminergic medications and in healthy older control subjects.

64 ischaemic stroke and 17 age-matched healthy control subjects.

65 FA and asthma, as well as healthy pediatric control subjects.

66 severe traumatic brain injury and 19 healthy control subjects.

67 verse cardiac outcomes compared with matched control subjects.

68 ts with functional movement disorders and 36 control subjects.

69 n 2013-2014 were included along with healthy control subjects.

70 re significantly greater in patients than in control subjects.

71 om postmortem human tissue from 49 AD and 42 control subjects.

72 and age-, race-, and gender-matched healthy control subjects.

73 t differed from correlations seen in healthy control subjects.

74 osis and 51,153 non-HCM age- and sex-matched control subjects.

75 response status and time point compared with control subjects.

76 ll death and annexin A5 levels compared with control subjects.

77 to Parkinson's disease patients and healthy control subjects.

78 ptic dopamine levels in 983 patients and 968 control subjects.

79 hment when compared with healthy age-matched control subjects.

80 the Genome Aggregation Database (gnomAD) as control subjects.

81 macula was conducted in patients and healthy control subjects.

82 patients with mild cognitive impairment and control subjects.

83 tissue samples of case workers compared with control subjects.

84 iagnosed with eczema, and healthy skin of 18 control subjects.

85 d 151 patients with BP and compared with 200 control subjects.

86 ith T2DM and 62 (1)H NMR spectra of urine of control subjects.

87 pean ancestry and 14,810 ancestrally matched control subjects.

88 diminished in patients with COPD compared to control subjects.

89 pared with age and sex-matched dementia-free control subjects.

90 s were compared between subgroups and normal control subjects.

91 ents (143 eyes) with MCI, and 137 (248 eyes) control subjects.

92 ion in unmedicated patients as compared with control subjects.

93 sity ratio of BD patients were compared with control subjects.

94 jects with type 2 diabetes mellitus than the control subjects.

95 articipants with cocaine use disorder and 35 control subjects.

96 8F-AV-1451 and 11C-PK-11195 PET, and matched control subjects (14 for 18F-AV-1451 and 15 for 11C-PK-1

97 om foetuses to adults with Down syndrome and control subjects (16 gestational weeks to 64 years), tot

98 ] [I-III] total score, 43.4 +/- 17.8) and 30 control subjects (18 men and 12 women; mean age, 62 +/-

99 patients with ATAA (4 women and 4 men) and 3 control subjects (2 women and 1 man).

100 Pre-ICI, GLS was similar between cases and control subjects (20.3 +/- 2.6% vs. 20.6 +/- 2.0%; p = 0

101 ements of currents in neurons derived from 4 control subjects, 3 patients with BD who were lithium re

102 nexposed: 26.82 +/- 8.36 mL/kg/min) than did control subjects (32.69 +/- 7.75 mL/kg/min; P for all <

103 A total of 90 subjects (35 control subjects, 36 medicated patients, and 19 unmedica

104 /L) and COPD (21.5 nmol/L) was lower than in control subjects (39.8 nmol/L; P = 0.001).

105 viation]; 10 men) and 11 age-matched healthy control subjects (54 years +/- 15; eight men) underwent

106 of European ancestry (9/1832) compared with control subjects (6/7509; relative risk=6; P=0.00067).

107 women, mean age 34.7 +/- 12.9 years) and 113 control subjects (64 women, mean age 23.5 +/- 8.4 years)

108 with SDB = 114.8 aggregation units [AU] vs. control subjects = 98.0 AU; P < 0.05) and COL antibody (

109 When compared with control subject after adjustments for sex and HDL-C leve

110 re and 42 patients (compared with 52 healthy control subjects) after an exposure-based CBT.

111 viduals with 22q11DS and 330 matched healthy control subjects (age range, 6-56 years; 49% female).

112 two frontal cortical brain regions from 214 control subjects aged 20-90 years.

113 G compared with patients with PXS and normal control subjects (all P < .001) without a difference bet

114 A subset of 20 cocaine users and 17 control subjects also underwent functional MRI imaging u

115 .056, p = .035) in both patients and healthy control subjects, although the association with attentio

116 icantly lower in Holocaust offspring than in control subjects, an effect associated with maternal Hol

117 using RNA sequencing of CNON cells from 111 control subjects and 144 individuals with schizophrenia.

118 A total of 28 MIS-C, 20 healthy control subjects and 20 classic Kawasaki disease (KD) pa

119 uripotent stem cells (iPSCs) from unaffected control subjects and 3 subjects with ASD with microdelet

120 tch cohorts were included, comprising 10,145 control subjects and 5283 persons with depression, estab

121 CCM images from 26 control subjects and 62 patients with type 1 diabetes wi

122 A total of 38 eyes from 38 control subjects and 73 eyes from 73 uveitis subjects we

123 [ADNI: n = 1149; 382 cognitively unimpaired control subjects and 767 cognitively impaired participan

124 fic metabolomic signature compared with both control subjects and asthmatic patients.

125 an elevated masking threshold compared with control subjects and bipolar disorder patients without p

126 d disadvantageous cognitive PGSs relative to control subjects and cognitively stable individuals.

127 nce, we found this target expressed in human control subjects and low-grade HD patients.

128 Mean macular sensitivity of control subjects and multiple sclerosis patients in deci

129 thicker frontal cortices compared with adult control subjects and other clinical groups.

130 ial cells (PBECs) were isolated from healthy control subjects and patients with COPD and infected wit

131 s in PBECs; this was similar between healthy control subjects and patients with COPD.

132 expression of SQOR in skin fibroblasts from control subjects and patients with mutations in Complex

133 re found between the quantitative metrics of control subjects and patients without choroidal involvem

134 es in 6,176 individuals with ADHD and 25,026 control subjects and prioritized genes by applying an in

135 bcortical volume differences between healthy control subjects and psychiatric patients from 11 mega-

136 Results were specific versus control subjects and replicated across two independent d

137 for 75 min after TESS, but not sham-TESS, in control subjects and SCI participants, suggesting a subc

138 rors on the masked priming task than healthy control subjects and the types of errors were consistent

139 or pancreata from birth through adulthood in control subjects and those at various stages of type 1 d

140 HD also had smaller intracranial volume than control subjects and those with OCD or ASD.

141 d a generalized PGS disadvantage relative to control subjects and were the only subgroup to differ si

142 ypogammaglobulinemia patients, 7 RV-infected control subjects, and 14 noninfected control subjects.

143 amounts of D-lactate and IL-10 compared with control subjects, and bacterial lactate increases IL-10

144 profiles that discriminated between CHR and control subjects, and between subgroups of CHR subjects

145 ) and MCI (B = 2.69; p < .001) compared with control subjects, and CVI was significantly lower in pat

146 s and emphysema, in lung tissue samples from control subjects, and in skin, nasal, and oral samples f

147 schizoaffective disorder or non-psychiatric control subjects, and key outcomes, stratified by hippoc

148 osed or unexposed to cardiotoxic therapy and control subjects, and to evaluate associations between t

149 ivors, and 26.3% (95% CI, 24.0% to 28.3%) of control subjects, and was associated with mortality (haz

150 tients with multiple sclerosis compared with control subjects; and (iii) periarteriolar changes, incl

151 cing Abeta in human neurons from nondemented control subjects, as well as subjects with familial AD a

152 ts at the baseline (for patients) or T1 (for control subjects) assessment and 39 pairs at the posttre

153 tal bronchopulmonary dysplasia and term-born control subjects at 19 years of age and compared with pr

154 bited significantly lower IOPs compared with control subjects at the 1-, 2-, and 3-month time points

155 comparing 103 pairs of matched patients and control subjects at the baseline (for patients) or T1 (f

156 thods: A total of 129 EP participants and 65 control subjects attended for a center-based evaluation

157 disorder, compared with age- and sex-matched control subjects, based on previous imaging studies show

158 th panic disorder (compared with 150 healthy control subjects) before and 42 patients (compared with

159 did not differ between patients with PAH and control subjects, BMP10 levels were lower in PAH females

160 ological anxiety (N=2,554 patients and 2,348 control subjects) both showed increased activation in th

161 IV, and VI had higher IOP estimates than the control subjects, but only MPS I and IV had higher corre

162 human blood and lung ILCs from asthmatic and control subjects by flow cytometry, ELISA, RNA sequencin

163 lumetric pressure in patients with HFpEF vs. control subjects: calf 16 +/- 4 mm Hg vs. 22 +/- 4 mm Hg

164 rtical regions in a large sample of PTSD and control subjects can potentially provide new insight int

165 At baseline, compared with control subjects, CHR individuals had high glutamate/glu

166 At baseline, compared with control subjects, CHR subjects (independent of outcome)

167 Compared with control subjects, cocaine users showed significantly inc

168 urrence in individuals with ADHD, absence in control subjects, complete coverage in copy number gains

169 izophrenia spectrum disorders and 36 healthy control subjects completed high-resolution positron emis

170 ith an eye condition and 104 visually normal control subjects completed the Child PedEyeQ (functional

171 al brushings were also obtained from healthy control subjects comprising of adolescents admitted for

172 = 206/381) and age-matched glucose-tolerant control subjects (control 1/control 2: n = 65/83) and su

173 -raft membrane domains in tissue from normal control subjects, depressed suicides, and depressed nons

174 The control subjects did not show significant differences fo

175 One treated (4%) and 3 control subjects died (19%, p = 0.14).

176 ed 66 schizophrenia patients and 143 healthy control subjects during performance of context updating

177 atients with psychotic disorders and healthy control subjects (F(1,62.85) = 0.48, p = .49).

178 n in loss aversion compared with age-matched control subjects (females, 11; males, 9).

179 uencing of 4913 schizophrenia cases and 6188 control subjects from Sweden.

180 ched 1:4 by age, sex, and comorbidities with control subjects from the background population without

181 -HF-5C2 (2-lead system) subjects relative to control subjects from the prior FIX-HF-5C (3-lead system

182 in 12 out of 15 patients and negative in 10 control subjects, giving a sensitivity rate of 71.4% (CI

183 per group with occluded [cases] and patent [control subjects] grafts) on plasma samples collected th

184 A total of 176 patients with dry eye and 33 control subjects >=50 years old were included.

185 s, 2 of 26 treated subjects (8%) and 0 of 13 control subjects had hearing impairment, as did 1 nonran

186 ients with schizophrenia (SCZs) from healthy control subjects (HCs).

187 cases that die at younger ages compared with control subjects; (ii) the association between systemic

188 en among IA case subjects but not in matched control subjects, implying gene expression dysregulation

189 lic PRKN/PINK1 mutations compared to healthy control subjects in a German cohort, supporting the conc

190 tients and 10 healthy age and gender-matched control subjects in this cross-sectional clinico-radiolo

191 nthesis capacity did not differ from that of control subjects in treatment-resistant patients (p > .3

192 , with best discrimination between cases and control subjects in younger patients.

193 ckness segments of colon of five CD and five control subjects, in primary cultures of rat enteric neu

194 veral other neuron types, more than IgG from control subjects, in three independent cohorts of patien

195 d between CUD case patients and cocaine-free control subjects, including previously implicated candid

196 Including genetic and phenotypic data of control subjects increased phenotypic similarity for all

197 lium of patients with diabetes compared with control subjects, independent of smoking, chronic obstru

198 tween the patients with BPVT and the matched control subjects (log-rank test, p = 0.79), but the form

199 IA (20 of 42 progressed to diabetes) and 25 control subjects matched for sex and age.

200 18 years; 45 men [54%]) were matched to 166 control subjects; matching was performed according to ag

201 method (mean age 49.6 years) and 50 healthy control subjects (mean age 31.3 years) were examined.

202 ion]) were compared with those in 10 healthy control subjects (mean age, 50.3 years +/- 17.2).

203 re Asthma Research Program-3) and 79 healthy control subjects.Measurements and Main Results: Gene exp

204 taken from adults with asthma or COPD versus control subjects.Measurements and Main Results: The mean

205 DB warranting adenotonsillectomy and healthy control subjects.Methods: Thirty children who had SDB wa

206 nts with NSAID-tolerant asthma (n = 21), and control subjects (n = 11).

207 els were also measured in a larger cohort of control subjects (n = 120) and patients with idiopathic

208 onsecutive patients with HFpEF (n = 285) and control subjects (n = 146) underwent invasive exercise t

209 41) and healthy age-, sex-, and BMI-matched control subjects (n = 20) were recruited.

210 recently abstinent CDSs (n = 24) and healthy control subjects (n = 36) both before and after 0.5 mg k

211 x with varying degrees of psychosis: healthy control subjects (n = 46), schizophrenia patients (n = 2

212 of skin microbiomes of patients with AD and control subjects (n = 49 and 189 samples), we identified

213 raline, or venlafaxine (8 weeks) and healthy control subjects (n = 59; age 18-65 years).

214 ementia with Lewy bodies (DLB, n = 415), and control subjects (n = 6,155).

215 sed 1- to 18 year-old patients (n = 962) and control subjects (n = 636) was used to construct abbrevi

216 weeks after infection (n = 109) and healthy control subjects (n = 98).

217 )-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (

218 ving an ICI who did not develop myocarditis (control subjects, n = 92).

219 distribution using 1,800 CAD cases and 1,163 control subjects newly recruited in India.

220 nd compared their ERG findings with those of control subjects (no diabetes).

221 tissue samples collected from DMPA users and control subjects not using hormonal contraception.

222 55,105 CRC-affected case subjects and 65,079 control subjects of European ancestry.

223 Patients with HFpEF and healthy control subjects of similar age and sex distributions (n

224 angiography images, matching each case to 3 control subjects on age, sex, county, and years of medic

225 There was no change in GLS among control subjects on an ICI without myocarditis (pre-ICI

226 s similar among patients with AD and MCI and control subjects on multivariable analysis (p > .05).

227 st adult clinical outcomes and differed from control subjects only in schizophrenia PGSs.

228 05), and 1 motif has 7 copies observed among control subjects only.

229 ticles contrasted either anxious patients to control subjects or an unpredictable-threat condition to

230 nd adults compared with levels in respective control subjects (P < .01).

231 anded across all AD age groups compared with control subjects (P < .05).

232 tor resting-state connectivity compared with control subjects (P < .05).

233 ithout retinopathy compared with age-matched control subjects (P < 0.001).

234 validated in schizophrenia cases and none in control subjects (p = .039), of which all were identifie

235 moving sled, with similar learning curves to control subjects (P = 0.87).

236 red in 13 (11%) cases with SCAD and 40 (12%) control subjects (p = 0.93).

237 d between 82 affected individuals and >4,900 control subjects (p = 1.04E-09); this effect was stronge

238 h AUD and 43 demographically matched healthy control subjects participated in the fMRI experiment to

239 bstance using CHR individuals and 14 matched control subjects participated in the study.

240 Compared with control subjects, patients with asthma and COPD had lowe

241 Relative to control subjects, patients with AUD showed significant h

242 erosis patients (r = 0.49, P = 0.01) but not control subjects (r = 0.15, P = 0.55).

243 Drug control subjects received primaquine, chloroquine, and u

244 n observed between cocaine users and healthy control subjects result from a history of drug use or in

245 viation between 0 and - 6 dB) and 68 healthy control subjects selected by Propensity Score Matching.

246 ns that distinguish individuals with TS from control subjects separately for children and adults (N =

247 Finally, healthy control subjects showed an inverse relationship between

248 d in a larger sample of 147 offspring and 40 control subjects that included the 31 previously studied

249 ed that in patients, compared to the healthy control subjects, the volume of the substantia nigra was

250 shifted from alveolar macrophages in healthy control subjects to a predominance of recruited monocyte

251 ythema migrans were more likely than matched control subjects to be symptomatic at baseline with a gr

252 osis participants and 11 age-matched healthy control subjects to undergo 7 T imaging of the cervical

253 ve mild cognitive impairment) and 29 healthy control subjects underwent baseline assessment with 18F-

254 4, and nonresponders, n = 15) and 26 healthy control subjects underwent detailed sensory profiling.

255 phrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectrosco

256 overlapping group of 33 schizophrenia and 29 control subjects underwent PET to measure the availabili

257 ients with ABCA4-related retinopathy and 110 control subjects underwent quantitative fundus autofluor

258 otic symptoms and 19 age- and sex-comparable control subjects underwent simultaneous fluorodihydroxyp

259 d gray matter (GM) changes in 34 T2DM and 88 control subjects using high-resolution T1-weighted image

260 les and 5 nonlesional samples) and 7 healthy control subjects, using 10x Genomics.

261 ith functional gait disorders and 17 healthy control subjects walked onto a stationary sled ('Before'

262 ion of choroidal parameters with AD, MCI, or control subjects was assessed using multivariable genera

263 ry (infection-negative systemic inflammation control subjects) was recruited.

264 ic-priming effect in patients (compared with control subjects) was reflected in suppressed neural act

265 ases with ICI myocarditis and, compared with control subjects, was lower among cases presenting with

266 from 49 HD gene carriers and 49 age-matched control subjects, we implemented a novel dynamical syste

267 ) data for 187 individuals with OGID and 969 control subjects, we show that pathogenic variants in EZ

268 Using lung tissues from IPF and control subjects, we showed that expression of TOLLIP ge

269 atients were 78, HCC without PVT were 60 and control subjects were 70 randomly selected.

270 best distinguished individuals with TS from control subjects were age specific.

271 t depressive symptoms and 10 matched healthy control subjects were analyzed as well.

272 h PXS, 84 eyes with PXG, and 44 eyes healthy control subjects were analyzed.

273 diabetes (48 with and 13 without DPN) and 12 control subjects were enrolled and underwent MRN, quanti

274 clear palsy-frontal subtypes) and 20 healthy control subjects were included.

275 eyes from 14 MS patients and 18 eyes from 9 control subjects were included.

276 5 patients; 96 hours, 20 patients) and in 35 control subjects were measured.

277 ounced autistic traits in a group of healthy control subjects were related to lower scores associated

278 esional skin of patients with AD and healthy control subjects were sampled at 2 time points separated

279 Cases and control subjects were similar in age, sex, and cancer ty

280 atients with the 15q13.3 microdeletion and 3 control subjects, were generated and converted into indu

281 12 svPPA patients and 12 healthy age-matched control subjects while reading irregular words (e.g. yac

282 mab treatment and become more similar to the control subjects, while non-responders tend to remain mo

283 s with laboratory-confirmed hepatitis A with control subjects who tested negative for HAV infection.

284 formed in 263 CHR individuals and 51 healthy control subjects, who were then clinically monitored for

285 Patients with SZ were distinguishable from control subjects with 0.91 accuracy, 77% sensitivity, an

286 patients could be classified against healthy control subjects with 78% sensitivity and 77% specificit

287 0 CA, 11 hypertrophic cardiomyopathy, and 10 control subjects with calculation of mean diffusivity, f

288 yptococcal (n = 12) meningitis and in heathy control subjects with neither infection (n = 10).

289 no differences between dry eye patients and control subjects with respect to reading speed (172 vs 1

290 onic schizophrenia (SCZ) compared to healthy control subjects, with even lower activity in treatment

291 ar cells from 17 children with asthma and 19 control subjects without asthma were stimulated in vitro

292 +/- 0.7% [54 +/- 7 mmol/mol]) and 11 healthy control subjects without diabetes (HbA(1c) 5.5 +/- 0.2%

293 se duration of 21 years with 54 well-matched control subjects without diabetes in a multimodal MRI pr

294 gate this, 10 HNF1A mutation carriers and 10 control subjects without diabetes were recruited for a d

295 with T2D (23 without DN, 28 with DN) and 10 control subjects without diabetes.

296 ginine-induced glucagon levels compared with control subjects without diabetes.

297 ores (1) distinguished patients with EG from control subjects without EG (P < .0001, area under the c

298 Patients with EG and control subjects without EG were enrolled across 9 Conso

299 from 185 subjects (patients with EG, n = 74; control subjects without EG, n = 111) were analyzed.

300 abase for patients with migraine and matched control subjects without migraine between 2007 and 2016.